购物车
- 全部删除
- 您的购物车当前为空
ARN-3236 是一种口服有活性的、具有选择性的盐诱导激酶2 (SIK2)抑制剂,它能够抑制SIK1 (IC50:21.63 nM)、SIK2(IC50<1 nM)和 SIK3(IC50:6.63 nM)。它具有抗肿瘤作用。
为众多的药物研发团队赋能,
让新药发现更简单!
ARN-3236 是一种口服有活性的、具有选择性的盐诱导激酶2 (SIK2)抑制剂,它能够抑制SIK1 (IC50:21.63 nM)、SIK2(IC50<1 nM)和 SIK3(IC50:6.63 nM)。它具有抗肿瘤作用。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 655 | 现货 | |
2 mg | ¥ 957 | 现货 | |
5 mg | ¥ 1,990 | 现货 | |
10 mg | ¥ 3,130 | 现货 | |
25 mg | ¥ 4,720 | 现货 | |
50 mg | ¥ 6,590 | 现货 | |
100 mg | ¥ 8,880 | 现货 | |
200 mg | ¥ 11,800 | 现货 | |
500 mg | ¥ 17,700 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,830 | 现货 |
产品描述 | ARN-3236 is an oral active and selective inhibitor of salt-inducible kinase 2 (SIK2), (SIK2, SIK1 and SIK3 with IC50s of <1 nM, 21.63 nM and 6.63 nM respectively). ARN-3236 Has anti-cancer activity. |
靶点活性 | SIK3:6.63.nM, SIK2:<1 nM , SIK1:21.63 nM |
体外活性 | Salt-inducible kinase 2 (SIK2) 在约30%的高级浆液性卵巢癌中过表达。ARN-3236在10株卵巢癌细胞系中抑制其生长,IC50范围为0.8至2.6 μmol/L,且ARN-3236的IC50与内源性SIK2表达呈负相关(Pearson r = -0.642, P = 0.03)。ARN-3236还增强了8/10细胞系以及SKOv3ip(P = 0.028)和OVCAR8异种移植瘤对紫杉醇的敏感性。至少在三个细胞系中观察到了协同作用。ARN-3236在间期中断核与中心体的连接,在有丝分裂中阻止中心体分离,导致前期停滞,引发凋亡性细胞死亡和四倍体形成。ARN-3236还抑制了AKT磷酸化并减弱了生存蛋白表达。 |
细胞实验 | SIK2 expression was determined in ovarian cancer tissue samples and cell lines.?ARN-3236 was tested for its efficiency to inhibit growth and enhance paclitaxel sensitivity in cultures and xenografts of ovarian cancer cell lines.?SIK2 siRNA and ARN-3236 were compared for their ability to produce nuclear-centrosome dissociation, inhibit centrosome splitting, block mitotic progression, induce tetraploidy, trigger apoptotic cell death and reduce AKT/survivin signaling. |
分子量 | 336.41 |
分子式 | C19H16N2O2S |
CAS No. | 1613710-01-2 |
Smiles | COc1ccc(-c2c[nH]c3nccc(-c4ccsc4)c23)c(OC)c1 |
密度 | 1.278 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 130 mg/mL (386.43 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容